The Aporia · GSK sees falling vaccine sales take shine off earnings

GSK sees falling vaccine sales take shine off earnings

Read the original at Evening Standard ↗

Cite

APA MLA Chicago

Williams, H. (2026, October 28). GSK sees falling vaccine sales take shine off earnings. Evening Standard. https://www.standard.co.uk/business/business-news/gsk-british-aj-bell-cambridge-stevenage-b1302631.html

Dated from the outlet's own feed. Check the original for its byline.

Quick Summary

GSK reported a drop in vaccine sales to £2.6 billion for the third quarter ending September 30, down from previous quarters due to reduced demand for its Shingrix and Arexvy vaccines. Despite this, core operating profits rose by 5% to £3.08 billion, surpassing market expectations of £2.93 billion on a constant currency basis. However, pre-tax profits declined to £1.94 billion from £2.5 billion the previous year. GSK's CEO, Luke Miels, faces challenges in developing new drugs to counteract the impending patent expiration for its HIV drug Dolutegravir and is implementing cost-cutting measures across research and development and support services roles.

Written locally by qwen2.5:14b on 2026-10-28, using this article's own text rather than the other coverage of the same event (that is the story summary below).

AI analysis runs on qwen2.5:14b, locally

Story summary

As of October 28, 2026, GSK reported a decline in vaccine sales by 2% to £2.6 billion for the quarter ending September 30, primarily due to reduced demand for its shingles vaccine Shingrix and respiratory virus shot Arexvy. Despite this, core operating profits rose by 5% to £3.08 billion, outperforming market expectations of £2.93 billion. However, pre-tax profits dropped to £1.94 billion from £2.5 billion the previous year. The company's stock price fell by 7% in morning trading as a result of the disappointing vaccine sales figures. Luke Miels, GSK’s CEO, emphasized focus on operational delivery and R&D acceleration to counteract upcoming patent expirations, particularly for its key HIV treatment dolutegravir.

Written for “GSK Earnings Report” on 2026-10-28, grounded in this article and the 0 other(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Signals How these are calculated →

Claims extracted

sentences that state something as happening or true

Uncertain

0 of 11 hedged ("reportedly", "may", "according to")

Leaning

not political

takes no side on a contested political question

Publisher signals

65/100

Evening Standard's corrections and hedging, across everything collected from it. Not a measure of accuracy.

Outlets on this story

Economy/Business

Same framing elsewhere

articles that frame the event the way this one does

Who wrote this

Holly Williams

80 article(s) here · 1 carrying a prediction

🔮 GSK revealed in first half results in July that annual costs are set to be cut by £1.9 billion over the next three years to fund investment, ramp up R&D and help offset the hit when one of its key HIV treatments, dolutegravir, comes off its patent.

2026-10-28 · assertive framing · GSK sees falling vaccine sales take shine off earnings

2026-10-28 · assertive framing · Chancellor set to U-turn on Isa allowance cut to £12,000 – reports

🔮 Chancellor set to U-turn on Isa allowance cut to £12,000 – reports Mr Healey is said to believe the allowance cut was the wrong tool to persuade Britons to invest more in stocks and shares and would rather look to educate savers on the benefits of equity investing, according to the Financial Times. Former chancellor Rachel Reeves announced the Isa cut for savers aged under 65 at the autumn budget last year, with the change set to come into effect in April 2027, as she looked to encourage investment in the stock market.

2026-10-28 · assertive framing · Chancellor set to U-turn on Isa allowance cut to £12,000 – reports

🔮 Royal Mail, whose owner International Distribution Services was bought last year by Czech billionaire Daniel Kretinsky, is rolling out major reforms that will result in second-class post only being delivered on alternate weekdays with Saturday second-class deliveries scrapped.

2026-10-26 · assertive framing · Royal Mail delays full rollout of postal overhaul until after Christmas

🔮 It said full-year results were now set to beat market expectations, given the “strong financial performance and meaningful strategic progress in the first nine months of 2026”.

2026-10-26 · assertive framing · Plus500 upgrades annual outlook amid jump in new customers

🔮 If other countries follow its lead, it could decide what growing up looks like for future generations.

2026-10-25 · assertive framing · 60 Minutes Transcript: Australia's under-16 social media ban

🔮 When Malinauskas announced that his state would legislate, the Australian national government quickly followed suit, with bipartisan support.

2026-10-25 · assertive framing · Australia's under-16 social media ban faces enforcement challenges

🔮 Secondary ticketing platform Viagogo has branded singer Raye’s move to manually review tickets as “absurd” and said bots will only be stopped if the primary market is opened up to create a “fairer” industry.

2026-10-18 · assertive framing · Viagogo calls for ticket market overhaul after Raye’s ‘absurd’ anti-bot measures

🔮 Suppliers can be left vulnerable when they have bought energy in advance at a high price and could then suffer financial losses if prices later tumble sharply and high numbers of customers switch to other firms in search of cheaper deals.

2026-10-16 · assertive framing · Ofgem planning action to cushion energy firms from wholesale price swings

🔮 The boss of the Trades Union Congress (TUC) backed the move, saying the tax rise on the “bumper profits” of bank would raise £2.25 billion a year, but the trade body for the banking sector, UK Finance, warned it would “weaken the UK’s competitiveness”.

2026-10-16 · assertive framing · Bank shares drop on reports Chancellor planning Budget tax raid

Also by Holly Williams

Chancellor set to U-turn on Isa allowance cut to £12,000 – reports

2026-10-28 · Evening Standard

Chancellor set to U-turn on Isa allowance cut to £12,000 – reports

2026-10-28 · Evening Standard

Royal Mail delays full rollout of postal overhaul until after Christmas

2026-10-26 · Evening Standard

Plus500 upgrades annual outlook amid jump in new customers

2026-10-26 · Evening Standard

Nothing else under this byline is closely related to this article, so these are simply their most recent.

All 80 articles by Holly Williams →

Narrative

Claims (11 extracted, 0 hedged)

GSK sees falling vaccine sales take shine off earnings The British pharmaceutical firm revealed vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles jab Shingrix and Arexvy shot for the respiratory virus RSV. asserted

demand → see → virus

Shares in the FTSE 100 group fell 7% in morning trading on Wednesday on the sales disappointment. asserted

Shares → fall → disappointment

This came despite GSK posting a 5% rise in core operating profits, excluding exceptional items and currency movements, to £3.08 billion for the third quarter, against the £2.93 billion expected in the market, as sales on a constant currency basis lifted 5%. asserted

sales → come → basis

The results showed sales of Shingrix fell 5% and Arexy tumbled 24% amid lower US sales. asserted

Arexy → show → sales

Earnings were helped higher by sales of speciality medicines, up 15% in the quarter, as well as cancer treatments, which jumped 23%. asserted

which → help → quarter

Luke Miels, chief executive of GSK, said: “We remain focused on operational delivery, execution and accelerating research and development.” asserted

We → say → research

He said: “Chief executive Luke Miels is under pressure to build up a pipeline of new drugs ahead of a patent cliff with the loss of exclusivity on its blockbuster HIV drug Dolutegravir. asserted

Miels → say → drug

“Miels has made progress on this front, reflected in the strong showing for the speciality medicines arm and recent reporting around a big increase in its cancer treatment pipeline, and is continuing to bring down costs throughout the business. asserted

Miels → make → business

“However, the latest update is a reminder Miels still has plenty of work to do.” asserted

Miels → do → work

GSK revealed in first half results in July that annual costs are set to be cut by £1.9 billion over the next three years to fund investment, ramp up R&D and help offset the hit when one of its key HIV treatments, dolutegravir, comes off its patent. asserted

one → reveal → patent

In February, it confirmed around 350 R&D jobs were going across the US and UK and in July it said some support services roles were being impacted by cost cutting, but did not reveal numbers. asserted

roles → confirm → numbers

GSK sees falling vaccine sales take shine off earnings

Quick Summary

AI analysis runs on qwen2.5:14b, locally

Story

Compared with similar articles

Signals How these are calculated →

How this is being covered How these are calculated →

Publisher

Who wrote this

Topics

Subjects

Narrative

Claims (11 extracted, 0 hedged)